MGST1 facilitates lymph node metastasis in papillary thyroid carcinoma
Overview
This study identifies MGST1 as a critical biomarker for lymph node metastasis in papillary thyroid carcinoma (PTC), linking it to mitochondrial metabolic reprogramming and immune evasion.
Background
Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, with lymph node metastasis (LNM) significantly impacting patient prognosis. Understanding the molecular mechanisms driving LNM is essential for improving risk stratification and treatment approaches.
Data Highlights
The study utilized a multi-omics approach, integrating transcriptomics and single-cell RNA sequencing, to identify MGST1 as a core driver of lymph node metastasis in PTC.
Key Findings
MGST1 was identified as a core predictor of lymph node metastasis in PTC through machine learning analysis.
The MGST1-based model achieved an AUC of 0.833 in external validation.
Pharmacological inhibition of MGST1 with Toxoflavin suppressed proliferation, migration, and invasion of PTC cells.
Inhibition of MGST1 reversed the 'immune-cold' phenotype by promoting IL-1β release and suppressing TGF-β1.
MGST1 was positioned at the terminal stage of dedifferentiation.
Clinical Implications
MGST1 serves as a potential biomarker for assessing metastatic risk in PTC patients. Targeting MGST1 may offer a novel therapeutic approach to enhance treatment outcomes for high-risk patients characterized by mitochondrial reprogramming and immune evasion.
Conclusion
The study highlights the importance of MGST1 in lymph node metastasis of PTC and suggests its potential as a therapeutic target. Further research is warranted to explore MGST1's role in clinical settings.
